Pacific Edge battles out proposed end of US Medicare coverage for Cxbladder tests

New Zealand company Pacific Edge (ASX: PEB) has updated its billing policies in the US for its range of Cxbladder non-invasive genomic urine tests for the detection and management of bladder cancer.

Related Keywords

New Zealand ,Pennsylvania ,United States ,Peter Meintjes , ,Pacific Edge ,Advance Beneficiary Notice ,Security Act ,Medicare Advantage ,